Cidara Therapeutics, Inc.

DB:20D0 Stock Report

Market Cap: €138.0m

Cidara Therapeutics Valuation

Is 20D0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 20D0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 20D0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 20D0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 20D0?

Key metric: As 20D0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 20D0. This is calculated by dividing 20D0's market cap by their current revenue.
What is 20D0's PS Ratio?
PS Ratio3.2x
SalesUS$44.65m
Market CapUS$143.75m

Price to Sales Ratio vs Peers

How does 20D0's PS Ratio compare to its peers?

The above table shows the PS ratio for 20D0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.3x
HPHA Heidelberg Pharma
12x16.6%€102.1m
2INV 2invest
8.1xn/a€62.7m
MDG1 Medigene
3x16.1%€22.5m
FYB Formycon
14x33.4%€848.4m
20D0 Cidara Therapeutics
2.9x6.6%€143.8m

Price-To-Sales vs Peers: 20D0 is good value based on its Price-To-Sales Ratio (2.9x) compared to the peer average (9.3x).

Price to Sales Ratio vs Industry

How does 20D0's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
20D0 3.2xIndustry Avg. 8.1xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 20D0 is good value based on its Price-To-Sales Ratio (2.9x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 20D0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

20D0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.2x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: 20D0 is expensive based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 20D0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€19.20
€25.50
+32.8%
14.7%€30.79€22.39n/a3
Nov ’25€11.70
€22.24
+90.1%
2.0%€22.70€21.79n/a2
Oct ’25€9.50
€22.24
+134.1%
2.0%€22.70€21.79n/a2
Sep ’25n/a
€22.24
0%
2.0%€22.70€21.79n/a2
Apr ’25€16.12
€86.09
+434.1%
26.7%€110.69€55.34n/a3
Mar ’25€12.30
€86.09
+599.9%
26.7%€110.69€55.34n/a3
Feb ’25€11.80
€86.09
+629.6%
26.7%€110.69€55.34n/a3
Jan ’25€13.84
€86.09
+522.0%
26.7%€110.69€55.34n/a3
Dec ’24€12.22
€86.09
+604.5%
26.7%€110.69€55.34n/a3
Nov ’24€14.60
€86.09
+489.7%
26.7%€110.69€55.34€11.703
Oct ’24€17.08
€86.09
+404.0%
26.7%€110.69€55.34€9.503
Sep ’24€13.68
€86.09
+529.3%
26.7%€110.69€55.34n/a3
Aug ’24€21.80
€86.09
+294.9%
26.7%€110.69€55.34n/a3
Jul ’24€19.94
€86.09
+331.7%
26.7%€110.69€55.34n/a3
Jun ’24€24.56
€86.09
+250.5%
26.7%€110.69€55.34n/a3
May ’24€18.96
€86.09
+354.1%
26.7%€110.69€55.34n/a3
Apr ’24€21.00
€86.09
+310.0%
26.7%€110.69€55.34€16.123
Mar ’24€30.96
€89.12
+187.8%
29.7%€119.85€55.31€12.303
Feb ’24€22.20
€89.12
+301.4%
29.7%€119.85€55.31€11.803
Jan ’24€13.76
€117.14
+751.5%
17.4%€149.94€93.71€13.844
Dec ’23€12.25
€111.13
+807.3%
29.0%€158.75€59.53€12.225
Nov ’23€11.88
€111.13
+835.1%
29.0%€158.75€59.53€14.605

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.90

7D

3.6%

1Y

75.1%

Perrigo

US$3.8b

Provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally.

PIG

US$27.00

7D

6.8%

1Y

-3.6%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

3.6%

1Y

22.9%